金城医药 (300233.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.9x

Market Cap

CNY 5.02B

MomentumView details →

1D Return

−5.08%

YTD Return

−6.22%

RSI (14)

45.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.9x

Market Cap

CNY 5.02B

RSI (14)

45.0

MomentumView details →

1D Return

−5.08%

YTD Return

−6.22%

ProfitabilityView details →

Gross Margin

36.14%

Net Margin

2.42%

EBITDA Margin

14.69%

ROE (TTM)

1.80%

ROA (TTM)

1.28%

Asset Turnover

0.53x

GrowthView details →

Revenue YoY

−12.59%

EPS YoY

−54.90%

FCF YoY

+125.92%

Revenue CAGR 3Y

−7.92%

EPS CAGR 3Y

−44.71%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

1.73x

Quick Ratio

1.38x

Div Yield

1.91%

Div Rate

CNY 0.25

Div Growth 1Y

−62.50%

Financials snapshotView financials →

Revenue (TTM)

2.77B

Net Income (TTM)

66.93M

Op. CF (TTM)

415.71M

Latest newsMore news →

Jincheng Pharmaceutical announced its first-half 2026 results: revenue of 1.447 billion yuan, up 6.40% year-on-year, and net profit attributable to shareholders of 139 million yuan, up 220.11% year-on-year.16d ago

Jincheng Pharmaceutical's wholly-owned subsidiary Jincheng Taier's dydrogesterone tablets and its controlling subsidiary Jincheng Jinsu's ertapenem sodium for injection are proposed winners in the 12th national centralized drug procurement, with proposed winning prices of 25.5 yuan/box and 44.5 yuan/box respectively.33d ago

Similar companies

威海广泰002111.SZ 瑞迪智驱301596.SZ 宇新股份002986.SZ 中科磁业301141.SZ 通灵股份301168.SZ 合众思壮002383.SZ Find similar companies →

Latest newsMore news →

Jincheng Pharmaceutical announced its first-half 2026 results: revenue of 1.447 billion yuan, up 6.40% year-on-year, and net profit attributable to shareholders of 139 million yuan, up 220.11% year-on-year.16d ago Jincheng Pharmaceutical's wholly-owned subsidiary Jincheng Taier's dydrogesterone tablets and its controlling subsidiary Jincheng Jinsu's ertapenem sodium for injection are proposed winners in the 12th national centralized drug procurement, with proposed winning prices of 25.5 yuan/box and 44.5 yuan/box respectively.33d ago